

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
VOLUME 104: POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES)
AND MALARIA
Lyon, France: 7-14 February 2012

LIST OF PARTICIPANTS

Members

Jürgen C. Becker, Medical University of Graz, Austria [unable to attend]
Maria-Teresa Bejarano, Karolinska Institutet, Sweden
Janet S. Butel, Baylor College of Medicine, USA
Pierre Coursaget, University François Rabelais, France
Tina Dalianis, Karolinska Institutet, Sweden [Subgroup Chair, exposure data]
Andrew Darnton, HSE – Health and Safety Executive, United Kingdom [unable to attend]
Silvia de Sanjosé, Catalan Institute of Oncology, Spain [Subgroup Chair, cancer in humans]
Joakim Dillner, Karolinska Institutet, Sweden¹
Eric A. Engels, National Cancer Institute, USA
Ajay Goel, Baylor University Medical Center, USA [not present for evaluation]
Jennifer Gordon, Temple University School of Medicine, USA
Sam Mbulaiteye, National Cancer Institute, USA
Robert Newton, University of York, United Kingdom [Overall Chair]
Michael Pawlita, German Cancer Research Centre, Germany [Subgroup Chair, mechanisms]
Rosemary Rochford, SUNY Upstate Medical University, USA
Dana E. Rollison, H. Lee Moffitt Cancer Center and Research Institute, USA
Ronit Sarid, Bar-Ilan University, Israel
Keerti V. Shah, Johns Hopkins School of Public Health, USA [Subgroup Chair, cancer in experimental animals]
Peter Odada Sumba, Kenya Medical Research Institute, Kenya
Marita Troye-Blomberg, Stockholm University, Sweden
Raphael Viscidi, The Johns Hopkins Hospital, USA
Mats Wahlgren, Karolinska Institutet, Sweden² [only present for part of the evaluations]
Axel zur Hausen, Maastricht University Medical Center, The Netherlands

Invited Specialists

Christopher B. Buck, National Cancer Institute, USA³
Yuan Chang, University of Pittsburgh Cancer Institute, USA⁴
Mauro Tognon, University of Ferrara, Italy⁵

¹ Visiting Scientist at the IARC at the time of the meeting

² Mats Wahlgren holds a patent in the U.S.A. on a malaria vaccine

³ Christopher Buck is a co-inventor on two current patent applications and one pending patent application covering technologies related to development of prophylactic vaccines against Merkel cell polyomaviruses, human polyomaviruses 6 and 7 (HPyV6 and HPyV7), JC and BK polyomaviruses.

⁴ Yuan Chang's laboratory identified Merkel cell polyomavirus in 2008 and the University of Pittsburgh has patent coverage for the virus sequence and diagnostic assays.

⁵ Mauro Tognon is a co-inventor of one pending patent application for an indirect ELISA assay for the detection of SV40-specific large T antigen antibodies.

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
VOLUME 104: POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES)
AND MALARIA
Lyon, France: 7-14 February 2012

Representatives of national and international health agencies

Donald G. Blair, Representative of the National Cancer Institute, USA

Observers

Edith Y. Roset Bahmanyar, Observer for GlaxoSmithKline Biologicals, Belgium⁶ [did not attend]

IARC secretariat

Rosita Accardi-Gheit, Section of Infections
Robert Baan, Section of *IARC Monographs*
Lamia Benbrahim Tallaa, Section of *IARC Monographs*
Véronique Bouvard, Section of *IARC Monographs (Responsible officer)*
Gary Clifford, Section of Infections
Jean-Damien Combes, Section of Infections
Isabelle Deltour, Section of Environment and Radiation
Catherine De Martel, Section of Infections
Fatiha El Ghissassi, Section of *IARC Monographs*
Silvia Franceschi, Section of Infections
Tarik Gheit, Section of Infections
Yann Grosse, Section of *IARC Monographs*
Neela Guha, Section of *IARC Monographs*
Michelle Iannacone, Section of Infections
Béatrice Lauby-Secretan, Section of *IARC Monographs*
Karen Müller (*Editor*)
Martyn Plummer, Section of Infections
Kurt Straif, Section of *IARC Monographs (Section Head)*
Bakary Sylla, Section of Infections
Maria Timofeeva, Section of Genetics
Massimo Tommasino, Section of Infections
Salvatore Vaccarella, Section of Infections
Magdalena B. Wozniak, Section of Genetics

NOTE REGARDING CONFLICTS OF INTERESTS: Each participant submitted WHO's Declaration of Interests, which covers employment and consulting activities, individual and institutional research support, and other financial interests. Participants identified as Invited Specialists do not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations. The Declarations were updated and reviewed again at the opening of the meeting.

⁶ Edith Roset Bahmanyar is employed by GlaxoSmithKline Biologicals, Belgium. She is involved in phase IV studies for the candidate RTS,S/AS vaccine.

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
VOLUME 104: POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES)
AND MALARIA
Lyon, France: 7-14 February 2012

NOTE REGARDING OBSERVERS: Each Observer agreed to respect the Guidelines for Observers at *IARC Monographs* meetings. Observers did not serve as meeting chair or subgroup chair, draft any part of a *Monograph*, or participate in the evaluations. They also agreed not to contact participants before the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.

Posted on 16 December 2011, revised 10 February